Engineering Medicines To Improve Patient Care

About Viridian

Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Our patient-centric model of innovation leverages proven biology and technology to efficiently craft medicines to meet the needs of patients and healthcare providers.

Viridian’s most advanced program, VRDN-001, is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), and is in development for the treatment of thyroid eye disease (TED). TED is a debilitating auto-immune disease that causes inflammation and fibrosis of the orbital tissues surrounding the eye, leading to proptosis, or bulging of the eyes, redness and swelling, diplopia (double vision), pain, and potential blindness. Current treatments options are limited and burdensome.

In August 2022, the Company announced positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED).  Access the news release and data deck.

Learn more about Viridian and our programs in our corporate presentation.

Viridian Group Photo

Leadership

Our leadership team comprises experienced individuals passionate about the potential of science and engineering to lessen the burden of disease.

Jonathan Violin

Jonathan Violin, Ph.D.

President, Chief Executive Officer and Co-Founder

Read Bio >
Angela She

Angela She, Ph.D.

VP, R&D Operations and Chief of Staff

Read Bio >
Barrett Katz

Barrett Katz, M.D., M.B.A.

Chief Medical Officer

Read Bio >
Carrie Melvin

Carrie Melvin

Chief Operating Officer

Read Bio >

Deepa Rajagopalan, M.D.

SVP, New Products and Portfolio Development

Read Bio >
Janielle Newland

Janielle Newland

SVP, Human Resources

Read Bio >
Kristian Humer

Kristian Humer

Chief Financial Officer and Chief Business Officer

Read Bio >
Lara Meisner

Lara Meisner

SVP, General Counsel

Read Bio >
Vahe Bedian

Vahe Bedian, Ph.D.

Chief Scientist and Co-Founder

Read Bio >

Board of Directors

Arlene Morris

Arlene Morris

Chief Executive Officer, Willow Advisors

Read Bio >
Peter Harwin

Peter Harwin

Managing Member, Fairmount Funds Management LLC

Read Bio >
Tomas Kiselak

Tomas Kiselak

Managing Member, Fairmount Funds Management LLC

Read Bio >
Jennifer Moses

Jennifer Moses

Chief Financial Officer, G1 Therapeutics

Read Bio >
Jonathan Violin

Jonathan Violin

President, Chief Executive Officer and Co-Founder

Read Bio >